These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 17383867)

  • 1. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Wexler LH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Goey AK; Schellens JH; Beijnen JH; Huitema AD
    Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
    Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
    Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
    Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
    J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview and historical development of dexrazoxane.
    Hellmann K
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective interventions for cancer patients receiving anthracyclines.
    van Dalen EC; Caron HN; Dickinson HO; Kremer LC
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD003917. PubMed ID: 21678342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW; Jensen PB; Sehested M
    Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
    Ky B; Carver JR
    Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.